



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

24 November 2015
EMA/HMPC/280080/2013
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Serenoa repens* (W. Bartram) Small, fructus

Final

The European Medicines Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Abe M, Ito Y, Oyunuzul L, Oki-Fujino T, Yamada S. Pharmacologically relevant receptor binding characteristics and 5 α -reductase inhibitory activity of free Fatty acids contained in saw palmetto extract. *Biol Pharm Bull* 2009, 32(4):646-650

Agbabiaka TB, Pittler MH, Wider B, Ernst E. *Serenoa repens* (saw palmetto): a systematic review of adverse events. *Drug Saf* 2009, 32(8):637-647

Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG. [Five-year experience in treating patients with prostatic hyperplasia patients with permixone (*Serenoa repens* "Pierre Fabre Medicament)]. [Article in Russian] *Urologiia*. 2002, 1:23-5

American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH). Edited by the American Urological Association Education and Research 2010

Argirović A, Argirović D. [Does the addition of *Serenoa repens* to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?]. *Vojnosanit Pregl* 2013, 70(12):1091-1096 [Serbian]

Avins AL, Bent S, Staccone S, Badua E, Padula A, Goldberg H, et al. A detailed safety assessment of saw palmetto extract. *Complement Ther Med* 2008, 16(3):147-154

Avins AL, Lee JY, Meyers CM, Barry MJ; CAMUS Study Group. Safety and toxicity of saw palmetto in the CAMUS trial. *J Urol* 2013, 189(4):1415-1420

Barnes J, Anderson LA, Phillipson JD. Herbal Medicines. 3rd ed. Pharmaceutical Press, London 2007, 521-529

Baron A, Mancini M, Caldwell E, Cabrelle A, Bernardi P, Pagano F. *Serenoa repens* extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells. *BJU Int* 2009, 103(9):1275-1283



- Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms: a randomized trial. *JAMA* 2011, 306(12):1344–1351
- Bayne CW, Donnelly F, Ross M, Habib FK. *Serenoa repens* (Permixon®): A 5 α -Reductase Types I and II Inhibitor-New Evidence in a coculture model of BPH. *Prostate* 1999, 40(4):232-241
- Bayne CW, Ross M, Donnelly F, Habib FK. The selectivity and specificity of the actions of the lipido-sterolic extract of *Serenoa repens* (Permixon®) on the prostate. *J Urol* 2000, 164(3 Pt1):876-881
- Bent S, Kane C, Shinohara K, Nehaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia. *N Eng J Med* 2006, 354(6):557-566
- Boccafoschi C, Annoscia S. Confronto fra estratto di *Serenoa repens* e placebo mediante prova clinica controllata in pazienti con adenomatosi prostatica. [*Serenoa repens* extract and placebo in prostatic benign hyperplasia: clinical results]. *Urologia* 1983, 50:1257–1268
- Booker A, Suter A, Krnjic A, Strassel B, Zloh M, Said M, et al. A phytochemical comparison of saw palmetto products using gas chromatography and 1H nuclear magnetic resonance spectroscopy metabolomic profiling. *J Pharm Pharmacology* 2014; 66(6):811-822
- Boyle P, Robertson C, Lowe F, Roehrborn C. Updated meta-analysis of clinical trials of *Serenoa repens* extract in the treatment of symptomatic benign prostatic hyperplasia. *BJU Int* 2004, 93(6):751-756
- Braeckman J. The extract of *Serenoa repens* in the treatment of benign prostatic hyperplasia : a multicenter open study. *Curr Ther Res* 1994,; 55: 776-85.
- Braeckman J, Denis L, de Leval J, Keuppens F, Cornet A, De Bruyne, et al. A double-blind, placebo-controlled study of the plant extract *Serenoa repens* in the treatment of benign hyperplasia of the prostate. *European Journal of Clinical Research* 1997a, 9:247–59
- Braeckman J, Bruhwylter J, Vandekerckhove K, Geczy J. Efficacy and safety of the extract of *Serenoa repens* in the treatment of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. *Phytother Res* 1997b, 11:558-563
- Bressler R. Herb-drug interactions. Interactions between saw palmetto and prescription medications. *Geriatrics* 2005, 60(11):32-34
- Breu W, Hagenlocher M, Redi K, Tittel G, Stadler F, Wagner H. Anti-inflammatory activity of Sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclo-oxygenase and 5-lipoxygenase metabolism. *Arzneimittelforschung* 1992a, 42:547-551
- Breu W, Stadler F, Hagenlocher M, Wagner H. Der Sabalfrucht-Extrakt SG 291. *Z Phytotherapie* 1992b, 13:107-115
- Breza J., Kliment J., Valansky L., Capova G. Phytotherapy of symptomatic benign prostatic hyperplasia using alcohol extract of *Serenoa repens* fruit (Prostamol Uno). *Urologia* 2005; 11: 6–10
- Bruminhent J, Carrera P, Li Z, Amankona R, Roberts IM. Acute pancreatitis with saw palmetto use: a case report. *J Med Case Rep* 2011, 5:414-419
- Canadian Prostate Health Council and CUA Guidelines Committee. Update: Guidelines for the management of benign prostatic hyperplasia 2009
- Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. *Prostate* 1996, 29(4):231-240

Carilla E, Briley M, Fauran F, Sultan CH, Duvilliers C. Binding of Permixon®, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. *J Steroid Biochem* 1984, 20(4):521-523

Casarosa C, Cosci di Coscio M, Fratta M. Lack of effects of a liposterolic extract of *Serenoa repens* on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. *Clin Ther* 1988, 10(5):585-588

Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant *Serenoa repens* in benign prostatic hyperplasia. *Br J Clin Pharmacol* 1984, 18(3):461-2

Chang DF, Braga-Mele R, Mamalis N, Masket S, Miller KM, Nichamin LD, et al. ASCRS White Paper: clinical review of intraoperative floppy-iris syndrome. *J Cataract Refract Surg* 2008, 34(12):2153-2162

Che Y, Hou S, Kang Z, Lin Q. *Serenoa repens* induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of STAT 3 signaling. *Oncol Rep* 2009, 22(2):377-383

Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature. *J Intern Med* 2001, 250(2):167-169

Chevalier G, Benard P, Cousse H, Bengone T. Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of *Serenoa repens* (Permixon®) supplemented with [1-¹⁴C]-lauric acid, [1-¹⁴C]-oleic acid or [4-¹⁴C]-beta-sitosterol. *Eur J Drug Metab Pharmacokinet* 1997, 22(1):73-83

Cockett AT, Aso Y, Denis L, Khoury S, Barry M, Carlton CE, et al. World Health Organisation Consensus Committee recommendations concerning diagnosis of BPH. *Prog Urol* 1991, Dec 1(6):957-972

Cukier J, Ducassou J, Le Guillou M, Leriche A, Lobel B, Toubol J. Permixon® versus placebo; résultats d'une étude multicentrique. *Comptes Rendus de Therapeutique et de Pharmacologie Clinique* 1985, 4:15-21

Dathe G, Schmid H. Phytotherapie der benignen Prostatahyperplasie (BPH) mit Extractum *Serenoa repens* (Permixon®). *Urologie* 1991, 31:220-223

De Bernardi di Valserra M, Tripodi AS, Contos S, Germogli R. *Serenoa repens* capsules: a bioequivalence study. *Acta Toxicol Ther* 1994, 15:21-39

De Combarieu E, Martinelli EM, Pace R, Sardone N. Metabolomics study of Saw palmetto extracts based on 1H NMR spectroscopy. *Fitotherapy* 2015, 102:56-60

De la Rosette J, Alivizatos G, Madersbacher S, Rioja Sanz C, Nordling J, Emberton M, et al. Guidelines on benign prostatic hyperplasia. Edited by the European Association of Urology 2009

De la Taille A. Therapeutic approach. The Importance of controlling prostatic inflammation. *Uropean Urology Supplements* 2013, 12:116-122

Debruyne F, Koch G, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, et al. Comparison of a phytotherapeutic agent (Permixon®) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. *European Urology* 2002a, 41:497-507

Debruyne F, Koch G, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, et al. Comparaison d'un produit de phytothérapie (Permixon®) et d'un alpha-bloquant (tamsulosine) dans le traitement de l'hypertrophie bénigne de la prostate: étude internationale randomisée d'une durée de 12 mois. *Progrès en Urologie* 2002b, 12:384-394

- Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, et al. Evaluation of the clinical benefit of Permixon® and tamsulosin in severe BPH patients—PERMAL study subset analysis. *Eur Urol* 2004, 45: 773-780
- Delfosse M. Drogues végétales et plantes médicinales. APB, Brussels 1998, 356-357
- Délos S, Carsol JL, Ghazarossian E, Raynaud JP, Martin PM. Testosterone Metabolism in Primary Cultures of Human Prostate Epithelial Cells and Fibroblasts. *J Steroid Biochem Mol Biol* 1995, 55: 375-383
- Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after the exclusion of placebo responders. *Clinical Drug Investigation* 1995, 5: 291–297
- Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. *Clin Drug Invest* 1995, 9: 291-297
- Di Silverio F, D'Eramo G, Lubrano C, Flammia GP, Sciarra A, Palma E, et al. Evidence that *Serenoa repens* extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. *Eur Urol* 1992, 21: 309-314
- Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, et al. Effects of long-term treatment with *Serenoa repens* (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. *Prostate* 1998, 37: 77-83
- Elghamry MI, Hänsel R. Activity and isolated phytoestrogen of shrub palmetto fruits (*Serenoa repens* Small), a new estrogen plant. *Experientia* 1969, 25(8): 828-829
- El-Sheikh MM, Dakkak MR, Saddique A. The effect of Permixon on androgen receptors. *Acta Obstet Gynecol Scand* 1988, 67(5): 397-399
- Emberton M. Definition of at-risk patients: dynamic variables. *BJU Int* 2006, 97 Suppl 2: 12-15
- Emili E, Lo Cigno M, Petrone U. Risultati clinici su un nuovo farmaco nella terapia dell'ipertrofia della prostata (Permixon®). *Urologia* 1983, 50: 1042–1048
- ESCOPE Monographs 2nd ed. *Serenoae repentis* fructus (Sabal fructus). Thieme Verlag, Stuttgart 2003, 477-486
- European Medicines Agency. Guideline on the clinical investigation for the treatment of urinary incontinence. CHMP 2013
- European Medicines Agency. Guideline on the clinical investigation of medicinal products for the treatment of urinary incontinence. 27 June 2013
- European Pharmacopoeia. Saw palmetto fruit. *Sabalís serrulata fructus*. Edition 07/2012: 1848
- Flach AJ. Intraoperative Floppy Iris Syndrome: Pathophysiology, Prevention, and Treatment. *Trans Am Ophthalmol Soc* 2009, 107: 234–239
- Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. *Urology* 2001, 58(6): 960-965
- Giannakopoulos X, Baltogiannis D, Giannakis D, Tasos A, Sofikitis N, Charalabopoulos K, et al. The lipidosterolic extract of *Serenoa repens* in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. *Adv Ther* 2002, 19: 285-296

- Giulianelli R, Pecoraro S, Sepe G, Leonardi R, Gentile BC, Albanesi L, et al. Multicentre study on the efficacy and tolerability of an extract of *Serenoa repens* in patients with chronic benign prostate conditions associated with inflammation. *Archivio Italiano di Urologia e Andrologia* 2012, 84:94-98
- Glemain P, Coulange C, Billebaud T, Gattegno B, Muszynski R, Loeb G. Tamsulosine avec ou sans *Serenoa repens* dans l'hypertrophie bénigne de la prostate: l'essai OCOS. [Tamsulosin with or without *Serenoa repens* in benign prostatic hyperplasia: the OCOS trial]. *Prog Urol* 2002, 12(3):395-403
- Goepel M, Hecker U, Krege S, Rübber H, Michel MC. Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro. *Prostate* 1999, 38(3):208-215
- Görne RC. Systematisches Review zur Therapie von Symptomen der unteren Harnwege (LUTS) mit und ohne benigne Prostatahyperplasie (BPH) mit alkoholischen Extrakten von Sägepalmenfrüchten. *Z Phytotherapie* 2014, 35:111-118
- Grasso M, Montesano A, Buonaguidi A, Castelli M, Lania C, Rigatti P, et al. Comparative effects of alfuzosin versus *Serenoa repens* in the treatment of symptomatic benign prostatic hyperplasia. *Arch Esp Urol* 1995, 48(1):97-103
- Gurley BJ, Gardner SF, Hubbard MA, Williams KW, Gentry WB, Carrier J, et al. In vivo assessment of botanical supplementation of human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle and saw palmetto. *Clin Pharmacol Ther* 2004, 76:428-440
- Gutiérrez M, Hidalgo A, Cantabrana B. Spasmolytic activity of a lipidic extract from *Sabal serrulata* fruits: further study of the mechanisms underlying this activity. *Planta Med* 1996a, 62:507-511
- Gutiérrez M, Garcia de Boto MJ, Cantabrana B, Hidalgo A. Mechanisms involved in the spasmolytic effect of extracts from *Sabal serrulata* fruit on smooth muscle. *Gen Pharmacol* 1996b, 27(1):171-176
- Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of *Serenoa repens* extract. *Prostate Cancer and Prostatic Dis* 2004, 7(3):195-200
- Habib FK, Ross M, Ho CK, Lyons V, Chapman K. *Serenoa repens* (Permixon®) inhibits the 5 alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. *Int J Cancer* 2005, 114(2):190-194
- Hänsel R, Keller K, Rimpler H, Schneider G. Hagers Handbuch der Pharmazeutischen Praxis. Drogen P-Z. Springer-Verlag, Berlin 1994, 680-687
- Helfand BT, Lee JY, Sharp V, Foster H, Naslund M, Williams OD, et al. Associations between improvements in lower urinary tract symptoms and sleep disturbance over time in the CAMUS trial. *J Urol* 2012, 188(6):2288-2293
- Helpap B, Oehler U, Weisser H, Bach D, Ebeling L. Morphology of benign prostatic hyperplasia after treatment with Sabal extract IDS 89 or placebo. Results of a prospective, randomized, double-blind trial. *J Urologic Pathol* 1995, 3:175-182
- Hiermann A. The contents of sabal fruits and testing of their anti-inflammatory effect. *Arch Pharm (Weinheim)* 1989, 322(2):111-114
- Hill B, Kyprianou N. Effect of Permixon on Human Prostate Cell Growth: Lack of Apoptotic Action. *Prostate* 2004, 61(1):73-80
- Hizli F, Uygur MC. A prospective study of the efficacy of *Serenoa repens*, tamsulosin, and *Serenoa repens* plus tamsulosin treatment for patients with benign prostate hyperplasia. *Int Urol Nephrol* 2007, 39(3):879-886

- Hostanska K, Suter A, Melzer J, Saller R. Evaluation of cell death caused by a ethanolic extract of *Serenoa repens* fructus (Prostasan) on human carcinoma cell lines. *Anticancer Res* 2007, 27(2):873-881
- Iehlé C, Délos S, Guiro O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5-alpha-reductase isoforms – a comparative study of selective inhibitors. *J Steroid Biochem Mol Biol* 1995, 54(5-6):273-279
- Iglesias-Gato D, Carsten T, Vesterlund M, Pousette A, Schoop R, Norstedt G. Androgen-independent effects of *Serenoa repens* extract (Prostasan®) on prostatic epithelial cell proliferation and inflammation. *Phytother Res* 2012, 26(2):259-264
- Jibrin I, Erinle A, Saidi A, Aliyu ZY. Saw palmetto-induced pancreatitis. *South Med J* 2006, 99(6):611-612
- Kaplan SA, Volpe MA, Te AE. A prospective 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis / chronic pelvic pain syndrome. *J Urol* 2004, 171(1):284-288
- Koch E. Pharmakologie und Wirkungsmechanismen von Extrakten aus Sabalfrüchten (*Sabal fructus*), Brennesselwurzeln (*Urtica radix*) und Kürbissamen (*Cucurbita peponis semen*) bei der Behandlung der benignen Prostatahyperplasie; in *Phytopharmaka VII*, Schulz V, Rietbrock N, Roots I, Loew D (Hrsg.): Steinkopff, Darmstadt 1995, 57-79
- Lapi F, Gallo E, Giocaliere E, Vietri M, Baronti R, Pieraccini G, et al. Acute liver damage due to *Serenoa repens*: a case report. *Br J Clin Pharmacol* 2010, 69(5):558-560
- Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T. Hexanic lipidosterolic extract of *Serenoa repens* inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, *in vitro*. *BJU Int* 2012, 110(6 Pt B):E301-307
- Löbelenz J. Extractum Sabal fructus bei benignen Prostatahyperplasie (BPH). *Therapeutikon* 1992, 6(1-2):34-37
- Loew D, Habs M, Klimm H-D, Trunzler G. *Phytopharmaka Report*. 2^{te} Auflage. Steinkopff Darmstadt 1999, 174-190
- Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, et al. Multiple doses of saw palmetto did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. *Clin Pharmacol Ther* 2003, 74(6):536-542
- Mattei FM, Capone M, Acconcia A. Medikamentöse therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme. *TW Urologie Nephrologie* 1990,2: 346–350
- Miroddi M, Carni A, Mannucci C, Moleti M, Navarra M, Calapai G. Hot flashes in a young girl: a wake-up call concerning *Serenoa repens* use in children. *Pediatrics* 2012, 130(5):1373-1376
- Mooiman KD, Maas-Bakker RF, Hendriks JJ, Bank PC, Rosing H, Beijnen JH, et al. The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzoyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxel. *J Pharm Pharmacol* 2014, 66:865-874
- Niederprüm HJ, Schweikert HU, Zänker KS. Testosterone 5-alpha-reductase inhibition by free fatty acids from Sabal serrulata fruits. *Phytomedicine* 1994, 1:127-133
- Palin MF, Faguy M, LeHoux JG, Pelletier G. Inhibitory effects of *Serenoa repens* on the kinetic of pig prostatic microsomal 5-alpha-reductase activity. *Endocrine* 1998, 9(1):65-69

- Paubert-Braquet P, Richardson FO, Servent-Saez N, Gordon WC, Monge MC, Bazan NG, et al. Effect of *Serenoa repens* extract (Permixon®) on estradiol/testosterone-induced experimental prostate enlargement in the rat. *Pharmacological Research* 1996, 34 (3/4):171-179
- Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P. Effect of the lipidic lipidosterolic extract of *Serenoa repens* (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. *Prostaglandins Leukot Essent Fatty Acids* 1997, 57(3):299-304
- Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P. Effect of the Lipidosterolic Extract of *Serenoa Repens* (Permixon®) and its major Components on Basic Fibroblast Growth Factor-Induced Proliferation of Cultures of Human Prostate Biopsies. *Eur Urol* 1998, 33:340-347
- Petrangeli E, Lenti L, Buchetti B, Chinzari P, Sale P, Salvatori L, et al. Lipido-sterolic extract of *Serenoa repens* (LSESr, Permixon) treatment affects human prostate cancer cell membrane organisation. *J Cell Physiol* 2009, 219(1):69-76
- Pytel YA, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud JP. Long-term clinical and biological effects of the lipidosterolic extract of *Serenoa repens* in patients with symptomatic benign prostatic hyperplasia. *Adv Ther* 2002, 19(6):297-306
- Pytel' IuA, Lopatkin NA, Gorilovskii LM, Vinarov AZ, Sivkov AV, Medvedev AA. The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia. *Urologiia* 2004, (2):3-7
- Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, Morrone S, et al. Effects of the lipidosterolic extract of *Serenoa repens* (Permixon®) on human prostatic cell lines. *Prostate* 1996, 29(4):219-230
- Reece-Smith H, Memon A, Smart CJ, Dewbury K. The value of Permixon® in benign prostatic hypertrophy. *Br J Urol* 1986, 58(1):36-40
- Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, et al. Comparison of finasteride (Proscar®), a 5-alpha reductase inhibitor, and various commercial plant extracts in vitro and in vivo 5-alpha-reductase inhibition. *Prostate* 1993, 22(1):43-51
- Roehrborn CG. Definition of at-risk patients; baseline variables. *BJU Int* 2006, 97 Suppl 2: 7-11
- Scaglione F, Lucini V, Pannacci M, Caronno A, Leone C. Comparison of the potency of different brands of *Serenoa repens* extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. *Pharmacology* 2008, 82(4):270-275
- Scaglione F, Lucini V, Pannacci M, Dugnani S, Leone C. Comparison of the potency of 10 different brands of *Serenoa repens* extracts. *Eur Rev Med Pharmacol Sci* 2012, 16(5):569-574
- Sinescu I, Geavlete P, Multescu R, Gangu C, Miclea F, Coman I, et al. Long-term efficacy of *Serenoa repens* treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. *Urol int* 2011, 86(3):284-289
- Sirab N, Robert G, Fasolo V, Descazeaud A, Vacherot F, Taille Ade L, et al. Lipidosterolic extract of *Serenoa repens* modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. *Int J Mol Sci* 2013, 14(7):14301-14320
- Shakir SA, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. *Drug saf* 2002, 25(6):467-471

Shi R, Xie Q, Gang X, Lun J, Cheng L, Pantuck A, et al. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. *J Urology* 2008, 179:610-615

Stepanov VN, Siniakova LA, Sarrazin B, Raynaud JP. Efficacy and tolerability of the lipidosterolic extract of *Serenoa repens* (Permixon®) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. *Adv Ther* 1999, 16(5):231-241

Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S, et al. Comparison of finasteride (Proscar®) and *Serenoa repens* (Permixon®) in the inhibition of 5-alpha reductase in healthy male volunteers. *Eur Urol* 1994, 26(3):247-252

Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, et al. Inhibition of androgen metabolism and binding by a liposterolic extract of '*Serenoa repens* B' in human foreskin fibroblasts. *J Steroid Biochem* 1984, 20:515-519

Sweetman SC. Martindale: the Complete Drug Reference. 36th ed. London 2009, 2192-2193

Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. *Serenoa repens* for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 2012, Issue 12

Tarayre JP, Delhon A, Laressergues H, Stenger A, Barbara M, Bru M, et al. Anti-edematous action of a hexane extract of the stone fruit of *Serenoa repens* Bartr. *Ann Pharm Fr* 1983, 41(6):559-570

Tasca A, Barulli M, Cavazzana A, Zattoni F, Artibani W, Pagano F. Trattamento della sintomatologia ostruttiva da adenoma prostatico conestratto di *Serenoa repens*. Studio clinico in doppio cieco vs. placebo. [Treatment of obstructive symptomatology caused by prostatic adenoma with an extract of *Serenoa repens*. Double-blind clinical study vs placebo]. *Minerva Urologica e Nefrologica* 1985, 37:87-91

Teschke R, Frenzel C, Schulze J, Eickhoff A. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. *World J Gastroenterol* 2013, 19(19):2864-2882

Ulbricht C, Basch E, Bent S, Boon H, Corrado M, Foppa I et al. Evidence-based Systematic Review of Saw Palmetto by the Natural Standard Research Collaboration. *J Soc Integr Onc* 2006, 4(4):170-186

Vacher P, Prevarsakaya N, Skryma R, Audy MC, Vacher AM, Odessa MF, et al. The Lipidosterolic Extract from *Serenoa repens* interferes with Prolactin Receptor Signal Transduction. *J Biomed Sci* 1995, 2(4):357-365

Vahlensieck W, Völp A, Lubos W, Kuntze M. Benigne Prostathyperplasie – Behandlung mit Sabalfrucht Extract. Eine Anwendungsbeobachtung an 1334 Patienten. [Benign prostatic hyperplasia--treatment with sabal fruit extract. A treatment study of 1,334 patients]. *Fortschr Med* 1993, 111(18):323-326

Van Coppenholle F, Le Bourhis X, Carpentier F, Delaby G, Cousse H, Raynaud JP, et al. Pharmacological Effects of the Lipidosterolic Extract of *Serenoa repens* (Permixon®) on Rat Prostate Hyperplasia Induced by Hyperprolactinemia: Comparison with Finasteride. *Prostate* 2000, 43:49-58

Van Hellemond J. Fytotherapeutisch Compendium. APB, Brussels 1985, 534-535

Vela Navarrete V, Garcia Cardoso JV, Barat A, Manzarbeitia F, López Farré A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammation markers. Markers of o a double blind pilot clinical assay. *European Urology* 2003, 44:549-555

Verhelst G. Groot handbook geneeskrachtige planten. 4^{de} druk. BVBA Mannavita 2010, Wevelgem 507-508

- Villanueva S, Gonzáles J. Coagulopathy induced by saw palmetto: a case report. *Bol Asoc Med P R* 2009, 101(3):48-50
- Wadsworth TL, Carrol JM, Mallinson RA, Roberts CT Jr, Roselli CE. Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells. *Endocrinology* 2004, 145(7): 3205-3214
- Wagner H, Flachsbarth H. A new antiphlogistic principle from *Sabal serrulata* I. *Planta Med* 1981, 41(3):244-251
- Wagner H, Flachsbarth H, Vogel G. A new antiphlogistic principle from *Sabal serrulata* II. *Planta Med* 1981, 41(3):252-258
- Wargo KA, Allman EI, Ibrahim F. A possible case of saw palmetto induced pancreatitis. *South Med J* 2010, 103(7):683-685
- Weinrobe MC, Montgomery B. Acquired bleeding diathesis in a patient taking PC-SPES. *N Engl J Med* 2001, 345(16):1213-1214
- Weisser H, Tunn S, Behnke B, Krieg M. Effects of the *Sabal serrulata* extract IDS 89 and its subfractions on 5-alpha-reductase activity in human benign prostatic hyperplasia. *Prostate* 1996, 28(5):300-306
- Weisser H, Behnke B, Helpap B, Bach D, Krieg M. Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the *Sabal serrulata* extract IDS 89 (Strogen®) or placebo. *Eur Urol* 1997, 31(1):97-101
- Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA. *Serenoa repens* extract for benign prostatic hyperplasia: a randomized controlled trial. *BJU Int* 2003, 92(3):267-270
- Williamson E, Driver S, Baxter K, editors. Stockley's Herbal Medicines Interactions. A guide to the interactions of herbal medicines. 2nd ed. The Pharmaceutical Press, London 2013, 415-417
- Yeu E, Grostern R. Saw palmetto and intraoperative floppy-iris syndrome. *J Cataract Refract Surg* 2007, 33(5):927-928
- Yue QY, Jansson K. Herbal drug Curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. *J Am Geriatr Soc* 2001; 49: 838.

References assessed but not sighted in the assessment report

- Braeckman J. The extract of *Serenoa repens* in the treatment of benign prostatic hyperplasia : a multicenter open study. *Curr Ther Res* 1994,; 55: 776-85.
- De Monte C, Carradori S, Granese A, Di Pierro GB, Leonardo C, De Nunzio C. Modern extraction techniques and their impact on the pharmacological profile of *Serenoa repens* extracts for the treatment of lower urinary tract Symptoms. *BMC Urology* 2014, 14:63-74